Tandem Diabetes Care Inc. | Small-cap | Healthcare
$16.25
-3.16%
| Tandem Diabetes Care Stock Comparison:
Tandem Diabetes Care vs Abbott LaboratoriesTandem Diabetes Care vs Boston ScientificTandem Diabetes Care vs UFP TechnologiesTandem Diabetes Care vs Alphatec HoldingsTandem Diabetes Care vs NovocureTandem Diabetes Care vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 940.2M
Gross Profit 489.6M 52.07%
Operating Income -99.1M -10.54%
Net Income -96.0M -10.21%
EPS (Diluted) -$1.47

Balance Sheet Metrics

Total Assets 967.7M
Total Liabilities 704.6M
Shareholders Equity 263.1M
Debt to Equity 2.68

Cash Flow Metrics

Operating Cash Flow 15.7M
Free Cash Flow -41.4M

Revenue & Profitability Trend

Tandem Diabetes Care Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue940.2M747.7M801.2M702.8M498.8M
Cost of Goods Sold450.6M380.0M388.2M326.6M238.3M
Gross Profit489.6M367.7M413.0M376.2M260.5M
Operating Expenses588.7M522.2M474.8M353.6M268.5M
Operating Income-99.1M-154.5M-61.8M22.7M-8.0M
Pre-tax Income-91.9M-220.3M-92.9M15.9M-36.3M
Income Tax4.2M2.4M1.7M335.0K-1.9M
Net Income-96.0M-222.6M-94.6M15.6M-34.4M
EPS (Diluted)-$1.47-$3.43-$1.47$0.24-$0.56

Income Statement Trend

Tandem Diabetes Care Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets724.5M748.0M850.0M811.5M637.2M
Non-Current Assets243.2M204.7M202.8M93.6M79.2M
Total Assets967.7M952.7M1.1B905.1M716.4M
Liabilities
Current Liabilities247.0M195.3M165.3M131.9M103.9M
Non-Current Liabilities457.5M443.8M447.5M340.2M246.3M
Total Liabilities704.6M639.0M612.8M472.0M350.1M
Equity
Total Shareholders Equity263.1M313.6M439.9M433.1M366.3M

Balance Sheet Composition

Tandem Diabetes Care Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-96.0M-222.6M-94.6M15.6M-34.4M
Operating Cash Flow15.7M-34.3M42.0M105.6M11.6M
Investing Activities
Capital Expenditures-19.2M-26.8M-34.1M-14.2M-27.4M
Investing Cash Flow22.9M-60.9M42.0M-177.5M-291.2M
Financing Activities
Dividends Paid-----
Financing Cash Flow45.1M-71.0K-675.0K0244.6M
Free Cash Flow-41.4M-83.4M7.5M87.8M-7.6M

Cash Flow Trend

Tandem Diabetes Care Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -13.04
Forward P/E -15.85
Price to Book 8.22
Price to Sales 1.30
PEG Ratio -15.85

Profitability Ratios

Profit Margin -18.71%
Operating Margin -14.71%
Return on Equity -92.31%
Return on Assets -6.17%

Financial Health

Current Ratio 2.30
Debt to Equity 320.75
Beta 1.52

Per Share Data

EPS (TTM) -$2.79
Book Value per Share $2.33
Revenue per Share $14.96

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
tndm1.3B-13.048.22-92.31%-18.71%320.75
Abbott Laboratories 231.9B17.314.7530.65%31.89%27.09
Boston Scientific 149.9B73.946.759.50%11.58%52.16
UFP Technologies 1.9B29.895.2019.36%11.59%55.05
Alphatec Holdings 1.6B-9.63-18.581,144.21%-25.77%-6.76
Novocure 1.9B-10.905.12-45.52%-26.41%192.49

Financial data is updated regularly. All figures are in the company's reporting currency.